NIBEC Co., Ltd.
KKRX:13861014,860.00
KRW
-210.00
(-1.39%)
ISIN
KR7138610001
Return %
Stock
S&P 500
1Y
-62.71
14.39
3Y
-3.13
81.42
5Y
-54.14
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jong-Pyeong Jeong
- Full Time Employees
- 93
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Jincheon-gun South Korea
- IPO Date
- Jul 13, 2011
- Website
- nibec.co.kr
- Similar Companies
- Business
- NIBEC Co., Ltd. is a South Korea-based biotechnology and medical device company that develops, manufactures, and commercializes peptide-based regenerative biomaterials, drug delivery systems, and therapeutic pharmaceuticals. Founded in 2000 and headquartered in Jincheon-gun, Chungcheongbuk-do, South Korea, with specialized research and development facilities in Seoul, the company operates across regenerative biomaterials, pharmaceutical therapeutics, contract development and manufacturing, and functional healthcare sectors. NIBEC Co., Ltd. provides a diversified portfolio of medical and dental biomaterial products, including OCS-B, a bovine-derived mineralized bone graft substitute for dental implantology and periodontics; OCS-B Collagen, an engineered bone graft composite integrating type I collagen with bovine bone mineral matrix; OCS-H, a synthetic hydroxyapatite bone graft substitute; GuideOss, a resorbable collagen barrier membrane for guided tissue and bone regeneration; Regenomer, a collagen-based matrix designed for tissue restoration and wound healing; CollaDerm, an absorbable dermal collagen matrix; and Clinplant, a surface-coating solution for dental and orthopedic implants. In its biotechnology and therapeutic development division, the company utilizes proprietary peptide engineering and drug delivery platforms, including TOPs (Targeting Peptide Platform) and NIPEP-TPP (Tissue and Cell-Penetrating Peptide Platform), to develop novel drug candidates such as NP-201 for the treatment of idiopathic pulmonary fibrosis and inflammatory bowel disease, NP-101 for osteoporosis, and targeted peptide-oligonucleotide therapeutics for oncological and metabolic indications. The company also operates a contract development and manufacturing organization (CDMO) business, providing custom peptide synthesis, GMP-grade peptide active pharmaceutical ingredient (API) manufacturing, analytical validation, and formulation development services to biopharmaceutical companies, alongside a line of peptide-infused functional oral care and anti-aging cosmeceutical products. NIBEC Co., Ltd. serves dental clinics, hospitals, academic institutions, and pharmaceutical enterprises across domestic and international markets, including North America, Europe, and the Asia-Pacific region, utilizing direct sales channels as well as original equipment manufacturer (OEM) and original design manufacturer (ODM) agreements with global dental and medical distributors. In recent developments, NIBEC Co., Ltd. has expanded its international regulatory compliance by securing European Medical Device Regulation (CE MDR) certifications for its core bone graft and collagen membrane products to accelerate market penetration across European territories. Additionally, the company has entered into collaborative development and material transfer agreements with multinational biopharmaceutical companies to apply its proprietary NIPEP-TPP platform to targeted oligonucleotide, siRNA, and mRNA therapeutic delivery, while expanding its GMP peptide production infrastructure and advancing global clinical evaluations for its lead peptide therapeutics.